Sutro Biopharma STRO Deferred Royalty Obligation Related To Sale Of Future Royalties Noncurrent
Deferred Royalty Obligation Related To Sale Of Future Royalties Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent?
- Sutro Biopharma (STRO) reported deferred royalty obligation related to sale of future royalties noncurrent of $229.11M in Q1 2026.
- How has Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent changed year-over-year?
- Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent increased by 20.4% year-over-year, from $190.3M to $229.11M.
- What is the long-term trend for Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent?
- Over 2 years (2023 to 2025), Sutro Biopharma's deferred royalty obligation related to sale of future royalties noncurrent has grown at a 21.3% compound annual growth rate (CAGR), from $149.11M to $219.54M.
- What does deferred royalty obligation related to sale of future royalties noncurrent mean?
- This represents the long-term liability associated with the upfront monetization of future royalty streams from drug candidates or intellectual property. It reflects the obligation to pay out future revenues to third-party investors who provided capital in exchange for a portion of those future earnings. This metric is critical for evaluating the company's long-term capital structure and the extent to which future cash flows are encumbered by past financing arrangements.